AVDL Avadel Pharmaceuticals plc

2.45
-0.25  -9%
Previous Close 2.7
Open 2.66
Price To Book 1.38
Market Cap 90679434
Shares 37,012,014
Volume 203,553
Short Ratio
Av. Daily Volume 151,013

SEC filingsSee all SEC filings

  1. SC 13D - General statement of acquisition of beneficial ownership 181229351
  2. 8-K - Current report 181227872
  3. 8-K - Current report 181181041
  4. 8-K - Current report 181173714
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181160624

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
Announced approval May 2 2016
Akovaz
Hypotension
Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
FT 218
Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy
Approved June 30 2014.
VAZCULEP (phenylephrine hydrochloride)
Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia
Approved Jun 3 2013
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery

Latest News

  1. Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors
  2. Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals — Future Expectations, Projections Moving into 2018
  3. As Waking Up Multiple Times a Night to Urinate Can Lead to Memory Deficits, Obesity, Lowered Sex Drive, Falls and Depression, a New Council Urges Awareness and Action
  4. Avadel: 3Q Earnings Snapshot
  5. Avadel Pharmaceuticals Reports Third Quarter 2018 Financial Results
  6. Avadel Presents Data on Quality of Life Improvement in Patients on NOCTIVA™ at American Urological Association Western Annual Meeting
  7. Avadel Pharmaceuticals to Report Third Quarter 2018 Financial Results
  8. New Research Coverage Highlights Dorian LPG, Avadel Pharmaceuticals, Pieris Pharmaceuticals, Resolute Energy, American Public Education, and THL Credit — Consolidated Revenues, Company Growth, and Expectations for 2018
  9. Avadel Pharmaceuticals Presents Data for NOCTIVA at 2018 American Urogynecologic Society Annual Scientific Meeting
  10. Avadel Pharmaceuticals Announces Journal of Urology Publication of Phase 3 Data on NOCTIVA
  11. Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference
  12. Brandes Investments Expands Stake in Avadel Pharmaceuticals
  13. Avadel Pharmaceuticals PLC Sponsored ADR to Host Earnings Call
  14. Breakfast Technical Briefing on Avid Bioservices and Three Other Additional Biotech Stocks

SEC Filings

  1. SC 13D - General statement of acquisition of beneficial ownership 181229351
  2. 8-K - Current report 181227872
  3. 8-K - Current report 181181041
  4. 8-K - Current report 181173714
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181160624
  6. 8-K - Current report 181158938
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181056311
  8. 8-K - Current report 181043362
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998995
  10. 8-K - Current report 18996447